4'-Acetoamido-4-hydroxychalcone, a chalcone derivative, inhibits glioma growth and invasion through regulation of the tropomyosin 1 gene

Biochemical and Biophysical Research Communications

Volumn 402, Issue 3, 2010, Pages 525-530

  Ku, Bo Mi ^a   Ryu, Hyung Won ^b   Lee, Yeon Kyung ^a   Ryu, Jinhyun ^a   Jeong, Joo Yeon ^a   Choi, Jungil ^a   Cho, Hee Jun ^b   Park, Ki Hun ^b   Kang, Sang Soo ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

Author keywords

Chalcone derivative; Glioma; Invasion; Tropomyosin

Indexed keywords

4' ACETOAMIDO 4 HYDROXYCHALCONE; ACTIN; ALPHA TROPOMYOSIN; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS FIBER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; TROPOMYOSIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78549242930     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.068     Document Type: Article

References (34)

1. Louis D.N., Pomeroy S.L., Caimcross J.G. Focus on central nervous system neoplasia. Cancer Cell 2002, 1:125-128.
2. Villano J.L., Seery T.E., Bressler L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol. 2009, 64:647-655.
3. Giese A., Bjerkvig R., Berens M.E., Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 2003, 21:1624-1636.
4. Preusser M., Haberler C., Hainfellner J.A. Malignant glioma: neuropathology and neurobiology. Wien. Med. Wochenschr. 2006, 156:332-337.
5. Hadjipanayis C.G., van Meir E.G. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J. Mol. Med. 2009, 87:363-374.
6. Gilbertson R.J., Rich J.N. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 2007, 7:733-736.
7. Martin-Villalba A., Okuducu A.F., von Deimling A. The evolution of our understanding on glioma. Brain Pathol. 2008, 18:455-463.
8. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
9. Cheng J.H., Hun C.F., Yang S.C., Wang J.P., Won S.J., Lin C.N. Synthesis and cytotoxic, anti-inflammatory, and anti-oxidant activities of 2',5'-dialsoxylchalcones as cancer chemopreventive agents. Bioorg. Med. Chem. 2008, 16:7270-7276.
10. Kumar S.K., Hager E., Pettit C., Gurulingappa H., Davidson N.E., Khan S.R. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. 2003, 46:2813-2815.
11. Lee S.A., Ryu H.W., Kim Y.M., Choi S., Lee M.J., Kwak T.K., Kim H.J., Cho M., Park K.H., Lee J.W. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 2009, 49:1316-1325.
12. Pandey M.K., Sandur S.K., Sung B., Sethi G., Kunnumakkara A.B., Aggarwal B.B. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J. Biol. Chem. 2007, 282:17340-17350.
13. Sasayama T., Tanaka K., Mizukawa K., Kawamura A., Kondoh T., Hosoda K., Kohmura E. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo. J. Neurooncol. 2007, 85:123-132.
14. Seo W.D., Kim J.H., Kang J.E., Ryu H.W., Curtis-Long M.J., Lee H.S., Yang M.S., Park K.H. Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:5514-5516.
15. Tate M.C., Aghi M.K. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009, 6:447-457.
16. Patan S. Vasculogenesis and angiogenesis. Cancer Treat. Res. 2004, 117:3-32.
17. Bharadwaj S., Prasad G.L. Tropomyosin-1, a novel suppressor of cellular transformation is downregualted by promoter methylation in cancer cells. Cancer Lett. 2002, 183:205-213.
18. Hughes J.A., Cooke-Yarborough C.M., Chadwick N.C., Schevzov G., Arbuckle S.M., Gunning P., Weinberger R.P. High-molecular-weight tropomyosins localize to the contractile rings of dividing CNS cells but are absent from malignant pediatric and adult CNS tumors. GLIA 2003, 42:25-35.
19. Lange K., Kammerer M., Saupe F., Hegi M.E., Grotegut S., Fluri E., Orend G. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 2008, 68:6942-6952.
20. Howe A.K. Regulation of actin-based cell migration by cAMP/PKA. Biochim. Biophys. Acta. 2004, 1692:159-174.
21. Perry S.V. Vertebrate tropomyosin: distribution, properties and function. J. Muscle Res. Cell Motil. 2001, 22:5-49.
22. Ono S., Ono K. Tropomyosin inhibits ADF/cofilin-dependent actin filament dynamics. J. Cell Biol. 2002, 156:1065-1076.
23. Gunning P.W., Schevzov G., Kee A.J., Hardeman E.C. Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol. 2005, 15:333-341.
24. Gunning P., O'Neill G., Hardeman E. Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol. Rev. 2008, 88:1-35.
25. Orend G. Potential oncogenic actin of tenascin-C intumorigenesis. Int. J. Biochem. Cell Biol. 2005, 37:1066-1083.
26. Varga A.E., Stourman N.V., Zheng Q., Safina A.F., Quan L., Li X., Sossey-Alaoui K., Bakin A.V. Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene 2005, 24:5043-5052.
27. Yager M.L., Hughes J.A., Lovicu F.J., Gunning P.W., Weinberger R.P., O'Neill G.M. Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma. Br. J. Cancer 2003, 89:860-863.
28. Zheng Q., Safina A., Bakin A.V. Role of high-molecular weight tropomyosins in TGF-beta-mediated control of cell motility. Int. J. Cancer 2008, 122:78-90.
29. Zhu S., Si M.L., Wu H., Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282:14328-14336.
30. Hughes J.A., Cooke-Yarborough C.M., Chadwick N.C., Schevzov G., Arbuckle S.M., Gunning P., Weinberger R.P. High-molecular-weight tropomyosins localize to the contractile rings of dividing CNS cells but are absent from malignant pediatric and adult CNS tumors. GLIA 2003, 42:25-35.
31. Pawlak G., Helfman D.M. Cytoskeletal changes in cell transformation and tumorigenesis. Curr. Opin. Genet. Dev. 2001, 11:41-47.
32. Hutterer M., Gunsilius E., Stockhammer G. Molecular therapies for malignant glioma. Wien. Med. Wochenschr. 2006, 156:351-363.
33. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8:610-622.
34. Inai T., Mancuso M., Hashizume H., Beffert F., Haskell A., Baluk P., Hu-Lowe D.D., Chalinsky D.R., Thurston G., Yancopoulos G.D., McDonald D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 2004, 165:35-52.